TABLE 5.

Multivariate analysis for prognostic factor affecting overall survival

Variable	Tested category	Reference category	Hazard ratio	Confidence interval	P‐value
Entire cohort
CCI	3	2	1.72	0.64‐4.66	.28
	≥4	2	5.52	1.81‐16.88	<.01
ECOG PS	≥2	0‐1	5.42	1.56‐18.85	.01
ELTS score	Intermediate	Low	2.07	0.68‐6.29	.20
	High	Low	2.65	0.64‐10.91	.18
ACA	Yes	No	2.81	0.79‐10.02	.11
Age (y)	61‐70	18‐60	0.86	0.22‐3.40	.82
	≥71	18‐60	2.22	0.65‐7.55	.20
Choice of initial TKI treatment	Imatinib	2GTKI	2.40	1.03‐5.62	.04
Imatinib cohort
CCI	3	2	0.73	0.15‐3.55	.70
	≥4	2	7.66	1.95‐30.14	<.01
ECOG PS	≥2	0‐1	2.45	0.41‐14.6	.32
ACA	Yes	No	4.43	0.93‐21.15	.06
ELTS score	Intermediate	Low	2.10	0.37‐12.08	.41
	High	Low	3.65	0.36‐37.44	.28
Age (y)	61‐70	18‐60	0.49	0.05‐4.73	.54
	≥71	18‐60	2.19	0.36‐13.3	.40
2GTKI cohort
CCI	3	2	6.26	1.39‐28.26	<.01
	≥4	2	3.67	0.32‐41.71	.29
ECOG PS	≥2	0‐1	15.32	2.47‐94.89	<.01
ACA	Yes	No	NE	NE	NE
ELTS score	Intermediate	Low	1.07	0.15‐7.45	.95
	High	Low	1.53	0.15‐16.04	.72
Age (y)	61‐70	18‐60	0.65	0.08‐5.42	.69
	≥71	18‐60	2.57	0.32‐20.39	.37

Abbreviations: 2GTKI, second‐generation tyrosine kinase inhibitor; ACA, additional chromosomal abnormality; CCI, Charlson Comorbidity Index; ECOG, Eastern Cooperative Oncology Group; ELTS, European Treatment and Outcome Study (EUTOS) long‐term survival score; NE, not estimable; PS, performance status.